J. Kelly Ganjei's most recent trade in INmune Bio Inc was a trade of 32,500 Option (right to buy) done . Disclosure was reported to the exchange on Dec. 5, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
INmune Bio Inc | J. Kelly Ganjei | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2024 | 32,500 | 32,500 | - | - | Option (right to buy) | |
INmune Bio Inc | J. Kelly Ganjei | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 12,500 | 12,500 | - | - | Option (right to buy) | |
INmune Bio Inc | J. Kelly Ganjei | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 35,000 | 35,000 | - | - | Option (right to buy) | |
INmune Bio Inc | J. Kelly Ganjei | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2022 | 35,000 | 35,000 | - | - | Option (right to buy) | |
INmune Bio Inc | J. Kelly Ganjei | Director | Grant, award, or other acquisition of securities at price $ 8.43 per share. | 21 Mar 2022 | 17,793 | 17,793 (0%) | 0% | 8.4 | 149,995 | Common Stock |
INmune Bio Inc | J. Kelly Ganjei | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 19,025 | 19,025 | - | - | Option (right to buy) | |
INmune Bio Inc | J. Kelly Ganjei | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 15,975 | 15,975 | - | - | Option (right to buy) |